. 2024 Aug 23;25(8):308. doi: 10.31083/j.rcm2508308

Table 4.

Baseline biochemical parameters of patients depending on 2^{-Δ⁢Δ⁢𝐂𝐭} quartiles.

2^{-Δ⁢Δ⁢Ct} quartiles	Groups	Q1	Q2–3	Q4	р; Q1 vs. Q4
	All (n = 216)	$<$ 3.9 (n = 54)	3.9–6.1 (n = 108)	$>$ 6.1 (n = 54)
	Men (n = 96)	$<$ 4.0 (n = 24)	4.0–6.3 (n = 48)	$>$ 6.3 (n = 24)
	Women (n = 120)	$<$ 3.7 (n = 30)	3.7–6.1 (n = 60)	$>$ 6.1 (n = 30)
TC, mg/dL	All	214.2 $\pm$ 50.1	205.8 $\pm$ 50.7	207.1 $\pm$ 51.1	NS
	Men	182.7 $\pm$ 53.4	203.2 $\pm$ 55.5	205.9 $\pm$ 54.9	NS
	Women	218.5 $\pm$ 48.9*	215.6 $\pm$ 52.0	215.2 $\pm$ 56.3	NS
TG, mg/dL	All	138 (102.0–183.0)	154.0 (104.3–234.5)	193.0 (133.0–245.0)	NS
	Men	133.0 (91.5–192.5)	139.5 (98.5–234.5)	201.5 (146.0–232.5)	NS
	Women	151.0 (118.0–183.0)1	153.0 (105.5–228.5)	163.5 (133.0–254.0)	NS
HDL-C, mg/dL	All	47.7 $\pm$ 15.1	47.5 $\pm$ 12.4	44.7 $\pm$ 10.6	NS
	Men	41.8 $\pm$ 8.5	44.6 $\pm$ 10.1	39.1 $\pm$ 6.5	NS
	Women	54.2 $\pm$ 16.8**	52.5 $\pm$ 13.6***	49.2 $\pm$ 11.3***	NS
VLDL-C, mg/dL	All	27.5 (20.0–37.0)	31.0 (21.0–46.8)	39.0 (27.0–50.0)	NS
	Men	26.5 (18.0–38.5)	28.0 (20.0–48.5)	41.0 (29.5–48.5)	NS
	Women	30.0 (24.0–37.0)	30.5 (21.0–45.5)	32.5 (27.0–51.0)	NS
LDL-C, mg/dL	All	128.9 $\pm$ 47.6	118.6 $\pm$ 48.7	117.0 $\pm$ 48.7	NS
	Men	105.4 $\pm$ 48.6	121.1 $\pm$ 48.1	113.3 $\pm$ 48.3	NS
	Women	131.4 $\pm$ 44.6	124.5 $\pm$ 50.0	120.0 $\pm$ 49.6	NS
ApoA-I, mg/dL	All	160.7 $\pm$ 37.0	146.8 $\pm$ 24.2	151.9 $\pm$ 28.3	NS
	Men	143.1 $\pm$ 21.3	137.3 $\pm$ 17.1	138.8 $\pm$ 19.5	NS
	Women	175.9 $\pm$ 35.3***	163.7 $\pm$ 32.1***	169.6 $\pm$ 30.1***	NS
ApoB, mg/dL	All	110.0 $\pm$ 31.2	106.8 $\pm$ 24.2	114.0 $\pm$ 31.0	NS
	Men	116.8 $\pm$ 39.1	100.3 $\pm$ 27.2	122.1 $\pm$ 34.5	NS
	Women	105.1 $\pm$ 24.4	113.4 $\pm$ 29.3*	101.9 $\pm$ 21.6*	NS
ApoB/ApoA-I	All	0.66 $\pm$ 0.26	0.74 $\pm$ 0.25	0.78 $\pm$ 0.25	NS
	Men	0.81 $\pm$ 0.27	0.74 $\pm$ 0.22	0.88 $\pm$ 0.23	NS
	Women	0.64 $\pm$ 0.24*	0.71 $\pm$ 0.28	0.63 $\pm$ 0.20***	NS
Lp(a), mg/dL	All	42.50 (10.0–80.0)	13 (9–21.5)	7.5 (5.0–20.0)	p $<$ 0.01
	Men	24.0 (6–60.5)	12.74 (6–52)	5 (3.5–19.0)	p $<$ 0.01
	Women	46.5 (10–80)	14 (7.5–45.5)	9 (6–20)	p $<$ 0.01
Glucose, mmol/L	All	5.4 (5.0–6.0)	5.4 (4.9–6.4)	5.5 (5.2–6.7)	NS
	Men	5.6 (5.0–7.4)	5.3 (4.9–6.1)	5.6 (5.4–6.8)	NS
	Women	5.4 (5.0–5.9)	5.2 (4.8–6.2)	5.5 (5.1–6.7)	NS
Insulin, mUl/mL	All	14.5 (10.6–20.1)	14.5 (10.2–19.6)	16.0 (12.5–24.0)	NS
	Men	15.2 (9.8–23.4)	15.4 (10.6–23.8)	17.4 (14.0–23.6)	NS
	Women	15.3 (11.8–23.4)	13.5 (10.0–16.7)	13.2 (11.5–24.3)	NS
hsCRP, mg/L	All	3.9 (2.0–7.2)	3.5 (1.8–6.6)	3.5 (1.4–6.9)	NS
	Men	2.9 (2.1–6.1)	2.8 (1.4–5.2)	3.2 (0.8–8.2)	NS
	Women	4.2 (2.0–8.2)	4.6 (1.8–6.6)	3.4 (1.5–6.1)	NS
PCSK9, ng/mL	All	243.0 (161.0–330.0)	190.5 (137.3–299.5)	194.3 (136.0–313.0)	NS
	Men	229.0 (178.0–372.0)	153.0 (121.0–254.0)	163.0 (127.0–216.5)	NS
	Women	258.0 (160.0–282.0)	227.0 (173.0–446.0)*	229.5 (159.0–426.5)	NS
Vitamin D, ng/mL	All	20.9 (12.5–27.3)	21.3 (15.3–30.2)	21.5 (16.4–28.7)	NS
	Men	24.0 (17.9–27.0)	18.5 (14.4–25.5)	23.9 (18.5–26.8)	NS
	Women	17.7 (11.0–27.9)	20.6 (11.3–29.7)	20.7 (16.0–29.0)	NS
Testosterone, ng/mL	All	0.3 (0.2–4.1)	1.9 (0.1–4.0)	0.7 (0.2–3.9)	NS
	Men	4.7 (3.7–5.0)	4.0 (2.8–5.4)	3.9 (2.6–4.1)	NS
	Women	0.2 (0.0–0.23)***	0.2 (0.1–0.2)***	0.2 (0.1–0.3)***	NS
Estradiol, pg/mL	All	12.5 (5.0–29.2)	16.4 (5.0–28.1)	13.8 (5.0–39.1)	NS
	Men	28.9 (15.4–39.7)	26.7 (18.0–35.2)	39.1 (20.4–46.8)	NS
	Women	5.0 (5.0–10.1)***	5.0 (5.0–7.6)***	5.0 (5.0–9.6)***	NS

*, p $<$ 0.05; **, p $<$ 0.01; ***, p $<$ 0.001 (intraquartile differences between males/females). NS, statistically non-significant between 4th and 1st quartiles. TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol; Apo, apolipoprotein; hsCRP, high-sensitive C-reactive protein; Lp(a), lipoprotein(a); PCSK9, proprotein convertase subtilisin/kexin type 9.